GLP-1 agonists are the most successful class of weight-loss drugs ever developed. Semaglutide produces 14.9% weight loss in Phase III trials. Tirzepatide reaches 22.5%. Retatrutide, the newest triple agonist, has reported 28.7%. None of these numbers were achievable with any prior pharmacotherapy. The curve keeps climbing as newer compounds add receptor mechanisms.
The shared starting point for the entire class is the GLP-1 receptor. Every drug in this category activates this single receptor as its primary mechanism. That includes liraglutide (approved 2010), semaglutide (Wegovy approved 2021), tirzepatide (Zepbound approved 2023), and retatrutide (Phase III, expected approval 2027). What differs between compounds is whether they activate additional receptors, how long they stay active in the body, and whether they are taken daily, weekly, or by mouth versus injection.
This article covers the mechanism in detail. It explains what the GLP-1 receptor is, where it lives in the body, what happens when it is activated, why the natural hormone lasts only minutes while the drug versions last days, and how the mechanism translates into the appetite suppression and weight loss that drives the category. For head-to-head comparisons of specific compounds see Semaglutide vs Tirzepatide. For the full class comparison see the GLP-1 Comparison Chart 2026.
What GLP-1 is and where the receptor lives
Glucagon-like peptide-1 is a 30-amino-acid peptide hormone released from intestinal L-cells (concentrated in the ileum and colon) in response to food intake. Within minutes of eating, GLP-1 levels in the bloodstream rise sharply, peak, and then fall back to baseline. The half-life of native GLP-1 is roughly two minutes. This is a deliberately short window calibrated to the duration of a meal.
The GLP-1 receptor (GLP1R) is a class B G-protein-coupled receptor expressed in several tissues. Each location contributes a different physiological effect when activated:
- Pancreatic beta cellsInsulin release in response to elevated blood glucose. This is the original mechanism that made GLP-1 attractive as a diabetes target. Importantly, the effect is glucose-dependent. Insulin is released only when blood sugar is high, which is why GLP-1 agonists carry low hypoglycaemia risk compared with insulin or sulfonylureas.
- Pancreatic alpha cellsSuppression of glucagon release. This complements the insulin effect, lowering blood glucose by reducing the body's signal to release stored glucose from the liver.
- Stomach and gastrointestinal tractSlowed gastric emptying. Food stays in the stomach longer, extending the fullness signal and slowing the rate at which carbohydrates reach the small intestine. This produces the characteristic delayed-satiety effect that participants describe as 'feeling full longer'.
- Hypothalamus and brainstemReduced appetite and food reward signalling. GLP-1 receptors in the arcuate nucleus and other appetite-regulating regions reduce hunger drive. Receptors in the brainstem and reward circuitry reduce the salience of food cues and the pleasure response to eating.
- Cardiovascular tissueReduced inflammation, modest blood pressure reduction, and cardioprotective effects independent of weight loss. The SELECT trial (Lincoff et al., NEJM, 2023, PMID: 37952131, NCT03574597) showed a 20% reduction in major adverse cardiovascular events with semaglutide in patients with established cardiovascular disease, in 17,604 participants over a median of 39.8 months.
The receptor distribution explains why GLP-1 agonists produce such a wide constellation of effects. They are not single-target drugs in the conventional sense. A single molecule binding a single receptor type produces effects in five organ systems, because that receptor is expressed in five organ systems. This is the strength and the weakness of the class. The breadth of effects produces remarkable efficacy. It also produces a spectrum of side effects (gastrointestinal, central nervous system, biliary) that is broader than what most drug classes show.
From a two-minute hormone to a once-weekly drug
The challenge of turning GLP-1 into a usable drug was its half-life. Native GLP-1 is broken down by the enzyme dipeptidyl peptidase-4 (DPP-4) in roughly two minutes. DPP-4 cleaves the second amino acid (alanine at position 2) off the N-terminus, producing an inactive metabolite. Any GLP-1 receptor agonist intended for therapeutic use must resist this cleavage or it will not last long enough to be useful.
The first GLP-1 agonist to reach the market, exenatide (Byetta), took a different route. Exenatide is a synthetic version of exendin-4, a peptide isolated from the saliva of the Gila monster lizard. Exendin-4 happens to share enough structural similarity with human GLP-1 to bind the GLP-1 receptor, but its sequence at position 2 (glycine instead of alanine) makes it resistant to DPP-4 cleavage. Exenatide was approved by the FDA in April 2005 for type 2 diabetes, with a half-life of roughly 2.4 hours requiring twice-daily injection.
The next generation engineered DPP-4 resistance directly into the GLP-1 backbone. Liraglutide (Victoza, approved 2010) substitutes alanine at position 2 with α-aminoisobutyric acid and adds a C16 fatty acid chain that binds serum albumin. The fatty acid extension (called acylation) is a key innovation. Once the molecule is bound to albumin, it is too large to be filtered by the kidneys, which extends the half-life to about 13 hours. Daily dosing becomes feasible.
Semaglutide (Ozempic, Wegovy) takes the same approach further with a longer C18 fatty acid chain and a different linker chemistry, extending the half-life to roughly seven days. Once-weekly dosing becomes standard. The same albumin-binding strategy extends to tirzepatide (C20 diacid, ~5 days) and retatrutide (C20 diacid with different linker, ~6 days). The acylation pattern is now the established design template for long-acting peptide drugs across the class.
Drug development timeline
The clinical trials that established the class are familiar names. Liraglutide's SCALE trial (Pi-Sunyer et al., NEJM, 2015, PMID: 26132939, NCT01272219) reported 8.0% weight loss at 3.0mg over 56 weeks. Semaglutide's STEP 1 trial (Wilding et al., NEJM, 2021, PMID: 33567185, NCT03548935) reported 14.9% at 2.4mg over 68 weeks. That was almost double the liraglutide figure at the same receptor. Tirzepatide's SURMOUNT-1 (Jastreboff et al., NEJM, 2022, PMID: 35658024, NCT04184622) reported 22.5% at 15mg over 72 weeks, adding the GIP receptor mechanism. Each step in the sequence reflected a meaningful improvement in either dose, duration, or receptor coverage.
What activation looks like in practice
Once a GLP-1 agonist is injected and reaches the bloodstream, the binding kinetics are straightforward. The drug binds the GLP-1 receptor with high affinity, the receptor activates its downstream G-protein cascade, and the physiological effects cascade outward over hours and days. Some effects appear within an hour of the first dose. Others build over weeks.
Day-one effects
Insulin secretion in response to a meal is detectable within an hour of the first dose. Most people notice reduced appetite at the next meal. Food tastes less appealing, portions feel larger, and the urge to snack between meals fades. Gastric emptying slows immediately, which is why nausea is most common with the first dose and the first day or two after each dose increase. The body has not yet adapted to slower-than-usual stomach motility.
Week-one effects
By the end of the first week, the appetite suppression is steady. Most people report eating roughly 20 to 30% less by volume, with smaller portions feeling satisfying. Cravings for high-reward foods (sweet, fatty, salty) typically fade. This is also when nausea peaks for most people, particularly if the starting dose was on the higher end. Slow titration protocols exist specifically to soften this peak.
Month-one effects
Measurable weight loss appears, typically 2 to 4% of body weight. The pace is faster in the first month than in subsequent months because the initial drop includes water weight from reduced caloric intake and glycogen depletion. By the end of month one, most people have completed at least one dose escalation step and are tolerating the drug well.
Six to twelve months
Maximum effect is reached. For semaglutide and tirzepatide, this means roughly 80 to 90% of total trial weight loss is achieved by month nine, with smaller gains continuing through month 18. After this point, weight stabilises at the new lower level so long as the drug continues. Discontinuation reverses the effect. STEP-4 (Rubino et al., JAMA, 2021, PMID: 33755728, NCT03548987) showed approximately two-thirds of lost weight returning within a year of stopping semaglutide. For practitioner-grade discussion of long-term safety see GLP-1 Safety Profile.
Why each compound differs at the receptor level
All approved GLP-1 agonists bind the same GLP-1 receptor. Their clinical differences come from three variables: how strongly they bind, what other receptors they touch, and how long they stay in circulation. The table below summarises the receptor-level differences across the class.
| Compound | Receptors | Half-life | Top-dose loss | Dosing |
|---|---|---|---|---|
| Liraglutide | GLP-1 | ~13 hr | 8.0% | Daily SC |
| Semaglutide | GLP-1 | ~7 days | 14.9% | Weekly SC |
| Tirzepatide | GLP-1 + GIP | ~5 days | 22.5% | Weekly SC |
| Retatrutide | GLP-1 + GIP + Glucagon | ~6 days | 28.7% | Weekly SC |
The pattern is consistent across the class. Each receptor added to the molecule adds roughly 5 to 7 percentage points of additional weight loss, suggesting that the mechanisms combine additively rather than compete. The retatrutide Phase II data (Jastreboff et al., NEJM, 2023, PMID: 37366315, NCT04881760) was the first human demonstration that triple agonism produced weight loss beyond what dual agonism could. TRIUMPH-4 (NCT05882045) confirmed this in Phase III at larger scale. This is the basis for the continued development of multi-receptor compounds. Whether quadruple agonism (GLP-1 + GIP + glucagon + amylin) or alternative receptor combinations continue the trend is an active research question, with several candidates in early clinical testing. For a deeper look at the mechanism question see Triple vs Dual Agonism.
Receptor selectivity also shapes the side-effect profile. GLP-1-only compounds (liraglutide, semaglutide) have a characteristic gastrointestinal profile dominated by nausea and delayed gastric emptying. Adding GIP appears to slightly improve GI tolerability. Adding glucagon introduces a new signal: dysesthesia (abnormal skin sensation) reported in retatrutide's TRIUMPH-4 at 20.9% in 12mg participants versus 0.7% on placebo. This signal is not seen in the GLP-1-only or GLP-1+GIP compounds. For mechanism-level discussion of why GIP and glucagon contribute differently see GLP-1 vs GIP.
Frequently Asked Questions
How do GLP-1 agonists work in simple terms?
GLP-1 agonists are drugs that activate the GLP-1 receptor, the same receptor that the body's natural GLP-1 hormone uses. Activating this receptor produces three weight-loss-relevant effects: insulin release from the pancreas in response to food, slower gastric emptying so meals stay in the stomach longer, and reduced appetite signalling in the brain. The combined result is lower blood glucose and reduced caloric intake.
What is GLP-1 and where does it come from?
GLP-1 stands for glucagon-like peptide-1. It is a hormone released from L-cells in the small intestine and colon in response to food intake. Its natural role is to coordinate the body's response to a meal: telling the pancreas to release insulin, telling the stomach to slow down, and telling the brain that feeding should stop. Native GLP-1 is broken down in roughly two minutes by the enzyme DPP-4, which is why drug versions are engineered to last days instead.
Why does the body break down natural GLP-1 so quickly?
The enzyme DPP-4 (dipeptidyl peptidase-4) cleaves the second amino acid off GLP-1, deactivating it within about two minutes of release. This is a feature of normal physiology. The body needs the GLP-1 signal to switch off quickly after a meal so that insulin release does not become excessive. GLP-1 agonist drugs are engineered with substitutions at this cleavage site to resist DPP-4, which is the structural change that gives them their multi-day half-lives.
Why do GLP-1 agonists cause nausea?
Slowed gastric emptying is the main cause. When the stomach empties more slowly than normal, food sits longer, and the resulting fullness can tip into nausea, especially during dose escalation. Direct GLP-1 receptor activity in the area postrema of the brain (the brain region responsible for vomiting) also contributes. Most people see nausea peak in the first one to two weeks after each dose increase, then decline as tolerance develops.
How do GLP-1 agonists differ from each other?
The main differences are receptor selectivity, half-life, and route of administration. Liraglutide and semaglutide bind only the GLP-1 receptor. Tirzepatide binds GLP-1 and GIP. Retatrutide binds GLP-1, GIP, and glucagon. Half-lives range from about 13 hours (liraglutide, daily dosing) to seven days (semaglutide, weekly). Most are subcutaneous injections, though oral semaglutide and the investigational orforglipron offer pill-form alternatives.
Do GLP-1 agonists work for people without diabetes?
Yes. The original approvals were for type 2 diabetes, but the same compounds at higher doses produce substantial weight loss in people without diabetes. Wegovy (semaglutide 2.4mg) and Zepbound (tirzepatide 5 to 15mg) are FDA-approved specifically for weight management in people with obesity or overweight with at least one weight-related comorbidity. The mechanism is the same. The difference is dose and labelled indication.
How long does it take for GLP-1 agonists to start working?
Appetite suppression typically appears within days of the first dose. Measurable weight loss usually shows up within two to four weeks, with maximum effect reached after roughly six to twelve months on the full dose. Trial endpoints are commonly measured at 56 to 72 weeks. Clinical guidelines suggest evaluating response after three to six months. If weight loss is below approximately 5%, switching compounds or adding adjunctive therapy is reasonable.
What happens when someone stops a GLP-1 agonist?
Most of the weight tends to come back. The STEP-4 trial (Rubino et al., JAMA, 2021, PMID: 33755728) showed that participants who stopped semaglutide regained roughly two-thirds of lost weight within a year. The mechanism is reversible. Once the drug clears, appetite returns to baseline and gastric emptying normalises. This is why current clinical thinking treats obesity pharmacotherapy as long-term maintenance rather than a finite course, similar to how blood pressure medication is used.
This article is for informational and educational purposes only and does not constitute medical advice. GLP-1 agonists are prescription medications with a range of indications, contraindications, and side effects. Retatrutide is investigational and has not been approved by the FDA, EMA, MHRA, or any other regulatory agency as of May 2026. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Last updated: May 2026.